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a  b  s  t  r  a  c  t
Deﬁning alterations in signalling pathways in normal and malignant cells is becoming a
major ﬁeld in proteomics. A number of different approaches have been established to iso-
late,  identify and quantify phosphorylated proteins and peptides. In the current report, a
comparison between SCX prefractionation versus an antibody based approach, both coupled
to  TiO2 enrichment and applied to TMT labelled cellular lysates, is described. The antibody
strategy was more complete for enriching phosphopeptides and allowed the identiﬁcationTMT
Titanium dioxide
of  a large set of proteins known to be phosphorylated (715 protein groups) with a minimum
number of not previously known phosphorylated proteins (2).
©  2015 The Authors. Published by Elsevier B.V. on behalf of European Proteomics
Association (EuPA). This is an open access article under the CC BY license
novel sites, or differentiate between different phospho-sitesMany  biological functions of living cells are regulated by phos-
phorylation/dephosphorylation of proteins. These reactions
are crucial in controlling key aspects of protein function,
including interactions in signalling pathways, activation or
inactivation and subcellular localization. Monitoring the sta-
tus of phosphorylation of proteomes became a major goal
in basic as well as in applied research because it offers a
unique tool to unravel signalling pathways and to identify cru-
cial nodes that can be altered during disease development.
∗ Corresponding author. Tel.: +44 020 7472 6200.
E-mail address: j.godovac-zimmermann@ucl.ac.uk (J.G. Zimmerman
http://dx.doi.org/10.1016/j.euprot.2015.01.002
2212-9685/© 2015 The Authors. Published by Elsevier B.V. on behalf of
article  under the CC BY license (http://creativecommons.org/licenses/b(http://creativecommons.org/licenses/by/4.0/).
Non MS-based strategies, mainly relying on the use of pro-
tein arrays, have been used in the past to identify kinases
substrates [1] or to unravel regulatory mechanisms of spe-
ciﬁc signalling pathways [2], but these approaches lack the
possibility to precisely map  the phosphorylation site, discovern).
within the same protein. For these reasons, plus the need for
high throughput studies, MS-based strategies are becoming
the methods of choice in the ﬁeld.
 European Proteomics Association (EuPA). This is an open access
y/4.0/).


























































ue u  p a o p e n p r o t e o 
Although MS-based strategies offer the best tool to pre-
isely identify and map  phospho-sites, two major issues
omplicate the detection of phosphorylations: (i) low stoichio-
etric abundance in the proteome, and (ii) low efﬁciency of MS
ragmentation and/or loss of the phosphoric group. At a given
ime, only a small proportion of the proteins present in a pro-
eome are phosphorylated and the phosphorylation status of
he same protein can vary within the same protein lysates
3]. Hence, enrichment strategies to speciﬁcally isolate phos-
hoproteins or phosphopeptides must be undertaken before
roceeding with mass spectrometry analysis. Furthermore,
dentifying and mapping phospho-sites in a sample requires
pecial care in setting up an appropriate MS–MS method-
logy. The CID approach, which is often used for peptide
equencing in shotgun proteomic experiments, is not nec-
ssarily the method of choice for maximal identiﬁcation of
hosphorylation sites. Because of the neutral loss occurring
or phosphoserine peptides and, to a lesser extent, for phos-
hothreonine peptides, sequencing information is often lost
ollowing the fragmentation of these peptides by CID. Many
ifferent fragmentation approaches have been tested and sug-
ested over recent years to address this issue, including MSA
4], HCD [5] and ETD [6], but a full consensus has not been
chieved for any of them. It seems that the success of one
pproach versus another depends on the sample complexity,
C-setup, and speciﬁc MS  settings [7]. Phosphotyrosine pep-
ides are even more  difﬁcult to identify, both because of the
ower level of tyrosine phosphorylation compared to serine
nd threonine [8] and because of the dynamic nature of tyro-
ine phosphorylation.
Further constraints may arise from the nature of the bio-
ogical samples. Our target is the telomerase immortalized
uman urothelial cell-line (TERT-NHUC) stably transfected
ith FGFR IIIb or with a fusion form of the same receptor
RT112FUS) [9]. To prevent malignant transformation, it is
ecessary to limit the number of passages for this cellular
ystem. This precludes metabolic labelling methods such as
ILAC and dictates the use of in vitro chemical labelling. This,
n turn, implies enrichment of peptides rather than proteins
ecause of the loss in trypsin digestion efﬁciency after chem-
cal labelling (due to lysine modiﬁcation with reporter tags)
nd this is applicable and cost effective for a limited amount
f sample (≤1 mg). The isobaric mass tag reagents iTRAQ or
MT  are the most commonly used compounds to label pep-
ides in vitro. They both are based on a N-hydroxysuccinimide
NHS) chemistry which allows them to react with every N-
erminus and -amine group of lysines, assuring that every
ryptic peptide could potentially be labelled. The main dif-
erence between iTRAQ and TMT  is the delta mass added to
ach labelled peptide and the molecular weight of the reporter
on generated after fragmentantion, which gives the relative
uantitation of each peptide. In terms of number of samples
hat can be simultaneously quantiﬁed, iTRAQ allows up to 8
ndependent analyses (iTRAQ 8-plex) while TMT  up to 10 (TMT
0-plex). These two reagents have been compared to assess
f one outperforms the other in terms of numbers of identi-
ed peptides/proteins and quantitation accuracy [10,11], but a
lear conclusion has not been determined. It seems that differ-
nt factors (e.g. scoring factors, search algorithms, instrument
sed) may affect the ﬁnal result [12,13] and choosing one 6 ( 2 0 1 5 ) 10–15 11
reagent over the other can just depend on the number of inde-
pendent samples handled. In this study, the TMT  6-plex has
been chosen.
We  present in this report a comparison of two  quantitative
phosphoproteomic workﬂows, both suitable to quantitatively
evaluate network dynamics in cells. Since it is known that
FGFR activation triggers a series of events involving tyrosine
phosphorylation [14], particular attention was paid to this spe-
ciﬁc modiﬁcation. Samples were subjected to two  different
workﬂows: (i) Strong Cation Exchange (SCX) chromatography
coupled to titanium dioxide enrichment (SCX + TiO2), and (ii)
phosphotyrosine immunoprecipitation coupled to phospho-
peptide enrichment of the unbound fraction after IP with
titanium dioxide (-pYs IP+ Unbound TiO2) (Fig. 1). To set up
the protocol, the A431 human epithelial carcinoma cell line
stimulated with EGF1 has been used. It is a well-known model
to study cancer associated signalling pathways and phosphor-
ylation events [15,16].
All samples were separated by reverse phase HPLC over
a 130 min  gradient before MS/MS (Buffer A: 0.1% formic acid
in water, Buffer B: 0.1% formic acid in acetonitrile; 0–1 min,
1% B; 1–90 min, 50% B; 90–91 min, 85% B; 91–111 min, 85% B;
111–112 min  85–1% B; 112–130 min, 1% B).
Cells were lysed by adding RIPA buffer containing protease
and phosphatase inhibitors and protein concentration was
measured using the DC protein concentration kit (Biorad).
800 g of proteins were reduced, alkylated and precipitated
overnight at 4 ◦C by adding 6 volumes (v/v) of cold acetone.
After centrifugation (15 min  at 10,000 × g), the resulting pel-
let was resuspended in 0.1 M of TEAB (triethyl ammonium
bicarbonate), trypsin was added at 1:100 ratio and digestion
was carried out for 16 h at 37 ◦C. The labelling reaction was
conducted using TMT reagents (Thermo Scientiﬁc), adding
1.6 mg  of labelling reagents and then following manufacturer’s
instructions. Labelling efﬁciency was evaluated by analysing
1/100 of the sample with a LTQ-Velos mass spectrometer
(Thermo Fisher Scientiﬁc) coupled to a Nanoacquity UPLC
(Waters, U.K.). Labelling efﬁciency was evaluated by counting
the number of peptides identiﬁed as labelled over the num-
ber of all identiﬁed peptides with a set F.D.R. of 0.05 and it
was estimated to be 97% (data not shown). Since labelling
follows extraction of the phosphopeptides, after ensuring a
suitable labelling procedure was available, the comparison
between the enrichment workﬂows described in the following
was conducted on unlabelled samples. The LTQ-Velos mass
spectrometer was set up as described by Johnson et al. [17]
basically the 10 most intense peaks detected in each cycle have
been fragmented by CID and HCD. The combination of these 2
approaches might increase the sensitivity of phosphopeptide
detection [18] and both fragmentation approaches are known
to be compatible with the TMT quantitative approach [19,20].
After trypsin digestion, samples were subjected either to
workﬂow 1 (SCX + TiO2) or to workﬂow 2 (-pYs IP + Unbound
TiO2). For workﬂow 1, the SCX procedure was performed
accordingly to Villen et al. [21] with the difference that the
fractionation was done using Mini Ion Exchange Spin Columns
(Thermo Scientiﬁc) that are more  suitable for the amount of
material available. Fractions were collected at: 5, 10, 15, 20, 25%
of Buffer B (30% CH3CN, 7 mM KH2PO4 pH = 2.7, 350 mM KCl) in
Buffer A (30% CH3CN, 7 mM KH2PO4 pH = 2.7); 100% of Buffer
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Fig. 1 – Overview of the experimental procedures. Schematic representation of workﬂow 1 (SCX prefractionation + titanium
dioxide enrichment) and Workﬂow 2 (IP + titanium dioxide enrichment). Underlined in bold are crucial nodes of each
ide; workﬂow. SCX: Strong Cation Exchange; TiO2: titanium diox
B, 100% of Buffer C (500 mM NaCl, 50 mM KH2PO4 pH = 7). In
addition, the column ﬂow through after sample loading and
the ﬁrst column wash with 100% of Buffer A were saved and
subjected to further phosphopeptide enrichment. A total of 9
fractions were collected, dried and then subjected to the phos-
phopeptide enrichment step using the TiO2 phosphopeptide
Enrichment kit (Thermo Scientiﬁc) followed by a clean-up step
with graphite columns (Thermo Scientiﬁc) according to man-
ufacturer’s instructions. The resulting samples were dried,
resuspended in 0.1% of formic acid and analyzed with the
LC–MS/MS system.
Workﬂow 2 was designed to couple a procedure speciﬁcally
aimed at enrichment of phosphotyrosine peptides with the
TiO2 enrichment strategy. Phosphotyrosine immunoprecipi-
tation was conducted by incubating 800 g of tryptic peptides
resuspended in IP buffer (100 mM Tris, 1% Nonidet P-40, pH
7.4) with Protein G agarose beads coupled to a mixture of 3
different anti-phosphotyrosine antibodies (pY100, 4G10 and
PT66) following the procedure described by Johnson et al. [17].
After overnight incubation with antibody beads, the sample
was brieﬂy spun down and the supernatant (unbound frac-
tion) was saved and dried for phosphopeptide enrichment
with TiO2 as described above. Phosphotyrosine peptides were
eluted by twice adding to the beads 70 l of 0.1 M Glycine,
pH 2. Both samples (the eluted fraction after IP and the TiO2
enriched sample) were dried, resuspended in 0.1% formic acid
and analyzed by LC–MS/MS.
For data analysis, Proteome Discoverer 1.3 was used,
searching against the UniProt human database with the Mas-
cot search engine. Up to 2 trypsin missed cleavages were
allowed, carbamidomethylation was set as a ﬁxed modiﬁ-
cation with methionine oxidation and phosphorylation of
serine, threonine and tyrosine as variable. Mass tolerance
was set to 10 ppm for the precursors and to 0.8 Da for the-pY IP: anti-phosphotyrosine Immuno precipitation.
fragments. The chosen false discovery rate was 0.05, with
subsequent manual validation of the peptides containing pY
[13,22,23].
Workﬂow 1 led to the identiﬁcation of 3121 peptides, corre-
sponding to 1183 protein groups, while workﬂow 2 identiﬁed
1720 peptides associated to 717 protein groups. However,
workﬂow 2 was more  speciﬁc than workﬂow 1 for identiﬁca-
tion of phosphopeptides, with a percentage of 43% versus 23%
(Fig. 2a). If only peptides identiﬁed from the “Unbound-TiO2”
fraction of workﬂow 2 are taken into account, then the speci-
ﬁcity of this protocol increases to 83% (Fig. 2b), clearly showing
that the phosphopeptide identiﬁcation rate from the IP proce-
dure was less satisfactory. Focusing on workﬂow 1 results, we
note that each SCX fraction (except for fraction 7), contributes
to the structure of the ﬁnal dataset of identiﬁed phosphopep-
tides by including peptides uniquely present in that fraction
(Fig. 2b). This shows that every fraction is enriching a speciﬁc,
unique pool of phosphopeptides.
Looking at the number of serines, threonines and tyrosines
identiﬁed as phosphorylated, the percentage of each of them
reﬂects the expected distribution within proteomes, with the
highest percentage given by phosphoserines (79–84% in our
datasets) and the lowest given by phosphotyrosines [8]. We
note that, compared to the phosphosite distribution evalu-
ated in a previous work, but with a different cell line (HeLa
cells) [24], both datasets shown here, have a higher propor-
tion of identiﬁed phospho-tyrosine sites (4% in workﬂow 1
and 3% in workﬂow 2), thus emphasizing the crucial role of
phosphotyrosines in EGF pathways. This result is promising
for workﬂow 1, where no speciﬁc step attempted to enrich
phosphotyrosines, while it is less satisfactory for workﬂow 2,
where a higher proportion of phosphotyrosines was antici-
pated. Conversely, phosphotyrosines were not detected with
TiO2 extraction alone (no immunoprecipitation), i.e. workﬂow
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Fig. 2 – Schematic summary of the two datasets. (a) Pie charts showing the percentage of non phosphorylated and
phosphorylated peptides recovered using the two workﬂows. (b) Histograms showing the distribution of non
phosphorylated peptides, non-redundant phosphorylated peptides and phosphorylated peptides identiﬁed in each fraction
of the two workﬂows. (c) Pie charts showing the percentage of phosphoserines, phosphothreonines and phosphotyrosines

















ihosphopeptides detected with workﬂow 1, workﬂow 2 or b
 enriched a set of phosphotyrosines that were only partially
etected with workﬂow 1.
At the level of identiﬁed protein groups, using workﬂow 2,
17 proteins were identiﬁed, of which 715 are known phospho-
roteins (based on the PhosphoSitePlus database [25]) while
ith workﬂow 1, 824 out of 1183 are known phospho-proteins
Fig. 2C). Focusing on those proteins identiﬁed based on pep-
ides enriched after immunoprecipitation, 335 (out of 386) are
nown to have phosphotyrosine sites (Supplementary Table
). Notably, the pS, pT and pY peptides identiﬁed with work-
ows 1 and 2 were only partially common (Fig. 2D). These
bservations suggest that three sources may constrain the
dentiﬁcation of phosphorylation sites: a lack of speciﬁcity in
uccessfully enriching phosphorylated peptides, loss of the
hosphate group during sample preparation and fraction-
tion, and unsuccessful MS/MS  analysis.
Supplementary Table 1 related to this article can be found,
n the online version, at doi:10.1016/j.euprot.2015.01.002.workﬂows.
To further explore this hypothesis, both datasets were
mined using the PhosphoSitePlus database to look for the
possible presence of (i) certain sources of contamination and,
(ii) for sequences known to be phosphorylated, but identiﬁed
as not phosphorylated in the current analysis. Contaminat-
ing peptides (i) can be grouped in 2 categories: peptides not
having serines, threonines or tyrosines in their sequences
(379 in workﬂow 1 and 104 in workﬂow 2) and peptides
containing these amino acids, but having a sequence not
previously reported to be phosphorylated (525 in workﬂow
1 and 311 in workﬂow 2). The ﬁrst group virtually certainly
represents contamination because there is no available evi-
dence (at the sequence, the database and the dataset level),
at the current state-of-the-art, that these sequences could
have a phosphorylated site. The second level of the anal-
ysis (ii) unravelled those peptides that present evidence of
possible phosphorylation (because they have already been
described as phosphorylated and they have been recovered
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Table 1 – The potential number of contaminant sequences identiﬁed in both workﬂows. S: Serine; T: Threonine; Y:
Tyrosine.
Sequences Workﬂow 1 Workﬂow 2
Total number of identiﬁed peptides 3121 1720
Total number of non-redundant identiﬁed sequences 2924 1626
Total number of peptides identiﬁed as not phosphorylated 2413 974
Total non-redundant sequences identiﬁed as not phosphorylated 2307 941
Number of peptides, identiﬁed as not phosphorylated and not containing S,T and Y 401  107
Number of non-redundant sequences, identiﬁed as not phosphorylated and not
containing S,T and Y
379  104
Number of peptides, identiﬁed as not phosphorylated, but containing S,T,Y 2012 867
Number of non-redundant sequences, identiﬁed as not phosphorylated, and containing
S,T,Y
1929  838
Number of non-redundant sequences, identiﬁed as not phosphorylated, containing
S,T,Y and known to be potentially phoshorylated
1405  526
Total number of potential contaminant sequences 904 415
Percentage of potential contaminant sequences over the number of non-redundant
sequences identiﬁed as not phosphorylated
39  44
total
rPercentage of potential contaminant sequences over the number of 
non-redundant sequences identiﬁed
after a speciﬁc phosphopeptide enrichment procedure). This
group might still contain contaminant peptides (i.e. peptides
known to be phosphorylated, but in cell lines different from
the one under investigation), but considering that a speciﬁc
enrichment strategy has been applied to all samples to iso-
late phosphopeptides, it is more  likely that the phosphosite
was not identiﬁed due to the loss of the phosphoric group
during the MS/MS  analysis or to an unsuccessful MS/MS anal-
ysis. Indications that this can be a substantial problem are
apparent in the 56 peptides that were detected in both work-
ﬂows, but were veriﬁed as phosphorylated in only one of
the workﬂows. This second group (ii) represents 48% of the
non-redundant identiﬁed sequences in workﬂow 1 and 26% in
workﬂow 2. In summary, as shown in Table 1, the ﬁnal number
of non-redundant, identiﬁed sequences, having no possibil-
ity to contain pS, pT or pY, is 904 for workﬂow 1 (30% of the
entire dataset) and 415 (25%) for workﬂow 2. Taken together,
these data suggest that workﬂow 2 has a slightly higher level of
speciﬁcity in enriching peptides from known phosphorylated
proteins and the resulting phosphopeptide dataset contains
approximately 75% peptides known to be phosphorylated.
The set of identiﬁed phosphotyrosine sites may still be
incomplete. The type of identiﬁed proteins suggest these sites
may be phosphorylated in the sample, but the subsequent
sample preparation, fractionation and MS  mapping compro-
mise the positive conﬁrmation of phosphorylation at these
sites. This could partially depend on the low abundance of
phosphotyrosines and partially on the presence of detergents,
coming from the sample preparation, which can affect the
overall ionization efﬁciency and subsequent MS/MS analy-
sis [26]. It is likely that removing interfering agents after
the immunoprecipitation would improve spectral quality and,
therefore, phosphotyrosine sites identiﬁcation [27].
In conclusion, to deﬁne the most productive approach
to a quantitative study of phospho-sites present in a
sample-limited cellular system, a comparison between a
phosphopeptide enrichment strategy coupling SCX fraction-
ation with TiO2 enrichment and an approach combining
phosphotyrosine enrichment and TiO2 enrichment of the
remaining phosphoserine and phosphothreonine containing31  26
peptides, has been conducted. Considering the number of
identiﬁed phospho-sites as well as the proportion of known
phosphopeptides and phosphoproteins ﬁnally detected, work-
ﬂow 2 gave slightly more  promising results and may still
be substantially improved by removing detergents after the
immunoprecipitation. Although the SCX prefactionation cou-
pled to TiO2 showed lower speciﬁcity, it has the potential to
unravel a higher number of peptides, thanks to the lysate
pre-fractionation performed before phosphopeptide isolation.
Conversely, although it has become a widely used procedure,
SCX prefractionation has been reported to have substantial
losses of hydrophobic phosphopeptides and poorer speciﬁcity
than reverse phase separations [28]. Jointly the two workﬂows
positively identiﬁed more  phosphorylation sites (1302) than
either workﬂow individually. That is, there still seems to be
room for improvements in commonly used phosphoproteome
protocols, especially in the context of sample-limited anal-
yses, and comprehensive coverage of phosphorylation sites
may require use of multiple protocols.
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